Quantum BioPharma Announces Corporate Updates

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Announces Corporate UpdatesToronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (\"Quantum BioPharma\" or the \"Company\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:Grant of Restricted Stock UnitsThe Company's board of directors (the \"Board\") authorized and approved the grant of restricted share units (each, an \"RSU\") pursuant to the Company's omnibus equity incentive plan (the \"Equity Incentive Plan\"). The Company granted 32,000 RSUs to each of Zeeshan Saeed, Anthony Durkacz and Donal Carroll (the \"RSU Grant\"). The RSUs granted vest upon the compilation of data which would enable the drafting of a Phase 2 MS Study.Stock Options GrantIn addition, the Company granted 98,000 options (the \"Options\") to acquire Class B subordinate voting shares in the capital of the Corporation (the \"Class B Shares\") at C$24.50 per Class B Share, pursuant to the Equity Incentive Plan to certain directors, officers, employees and consultants (the \"Option Grant\"). The Options granted vest immediately and expire September 24, 2030.Statutory Hold Period and Restrictions on ResaleThe Options and RSUs (and any Class B Shares issuable upon their settlement or exercise) are subject to a statutory hold period of four months and one day, and were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein. Related Party TransactionThe RSU Grant and the Option Grant, as they relate to the directors of the Company, constitutes a \"related party transaction\", as such term is defined in Multilateral Instrument 61-101 - Protection of Minority Shareholders in Special Transactions (\"MI 61-101\") due to the grants to the directors, who are members of the Board, and would require the Company to receive minority shareholder approval for, and obtain a formal valuation for the subject matter of, the transaction in accordance with MI 61-101, ...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B